Evidence map›Paper›PMID 35405177›Full record

ArticleJournal of affective disorders2022

The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.

Adam Bayes, Brooke Short, Carlos A Zarate, Lawrence Park, James W Murrough, Declan M McLoughlin, Patricio Riva-Posse, Robert Schoevers, Jolien Veraart, Sagar Parikh and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of affective disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Adam BayesBlack Dog Institute, UNSW Sydney, Australia; School of Psychiatry, UNSW Sydney, Australia. Electronic address: a.bayes@unsw.edu.au.
Brooke ShortSt Vincent's Hospital, Sydney, Australia.
Carlos A ZarateDivision of Intramural Research Program, National Institute of Mental Health, MD, United States.
Lawrence ParkDivision of Intramural Research Program, National Institute of Mental Health, MD, United States.
James W MurroughDepression and Anxiety Centre for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Declan M McLoughlinDepartment of Psychiatry, Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland.
Patricio Riva-PosseDepartment of Psychiatry and Behavioral Sciences at Emory University, Atlanta, GA, United States.
Robert SchoeversThe University Medical Center Groningen, Groningen, the Netherlands.
Jolien VeraartThe University Medical Center Groningen, Groningen, the Netherlands.
Sagar ParikhDepartment of Psychiatry, University of Michigan, MI, United States.
Paul GlueUniversity of Otago, Dunedin, New Zealand.
Johnson FamDepartment of Psychological Medicine, National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Rupert McShaneDepartment of Psychiatry, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
Veronica GalvezCorporacio Sanitaria Parc Tauli, Universitat Autonoma de Barcelona, I3PT, Institut d'Investigacio i Innovacio Parc Tauli, Sabadell, Barcelona, Spain.
Donel MartinBlack Dog Institute, UNSW Sydney, Australia.
Phern-Chern TorInstitute of Mental Health, Singapore.
Andre R BrunoniLaboratory of Neurosciences (LIM-27), Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da USP, Brazil.
Colleen K LooBlack Dog Institute, UNSW Sydney, Australia; School of Psychiatry, UNSW Sydney, Australia.

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS ZIA MH002857
6 · The paper itself

Abstract

objectivesOn a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice.

methodsAn international group of psychiatrists discussed the issue of safety of ketamine and esketamine and came to a consensus on key safety gaps.

resultsThere is no standard safety monitoring for off-label generic ketamine. For intranasal esketamine, each jurisdiction providing regulatory approval may specify monitoring. Treatment is often provided beyond the period for which safety has been demonstrated, with no agreed framework for monitoring of longer term side effects for either generic ketamine or intranasal esketamine. LIMITATIONS: The KSET has established face and content validity, however it has not been validated against other measures of safety.

conclusionsWe recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects.

Indexed as

Depressive Disorder, Treatment-ResistantDrug-Related Side Effects and Adverse ReactionsKetaminePsychiatryAdministration, IntranasalAntidepressive AgentsHumansAntidepressive AgentsKetamineAntidepressantMaintenanceSafetySide effects

Identifiers

PMID35405177
PMCPMC9133168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.